Magazine Article | January 9, 2018

Can Joseph Papa Save Valeant?

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

There’s no doubt about it — Joseph Papa took a huge risk and may have made a huge mistake. At the pinnacle of a firestorm of negative headlines and government investigations into Valeant Pharmaceuticals, Papa decided to take the helm of the embattled company, leaving behind a nearly 10-year successful career as chairman and CEO of OTC and generics drugmaker Perrigo.

It’s a story that has been quietly unfolding since Papa succeeded Michael Pearson in May 2016. But a little quiet is something this company likely relishes these days. For now, free of the media’s spotlight, Papa and his staff can continue with what he refers to as “the turnaround opportunity of a lifetime.”

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader